ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 78.37 |
| Open | 78.77 |
| Bid | 79.10 x 1000 |
| Ask | 84.50 x 1300 |
| Day's Range | 78.77 - 81.01 |
| 52 Week Range | 60.27 - 124.22 |
| Volume | 504,297 |
| Avg. Volume | 733,443 |
| Market Cap | 8.973B |
| Beta (3Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.25 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 113.11 |
- Insider Monkey
BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals (ARWR)
BioBoyScout, founded by Intellectual Property attorney Robert Toczycki, JD, MBA, has developed online biotech valuation calculators that enable small investors to compete with the big Wall Street institutions. The calculators can be modified to a user’s liking and apply the same financial valuation models used by most Wall Street analysts. BioBoyScout began developing its models […]
- Zacks
Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.
- Zacks
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
- Business Wire
Alnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the 2019 International Congress on Porphyrins and Porphyria , being held September 8-11, 2019 in Milan, Italy.
- Business Wire
Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare company, announced today a U.S. GI disease education and promotional agreement for Alnylam’s givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the potential treatment of AHP. Givosiran has received Priority Review designation and Breakthrough Therapy Designation from the U.S. FDA, as well as Orphan Drug Designation in the U.S. The Prescription Drug User Fee Act (PDUFA) date for givosiran is set for February 4, 2020.
- Business Wire
Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare company, announced today a U.S. GI disease education and promotional agreement for Alnylam’s givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the potential treatment of AHP. Givosiran has received Priority Review designation and Breakthrough Therapy Designation from the U.S. FDA, as well as Orphan Drug Designation in the U.S. The Prescription Drug User Fee Act (PDUFA) date for givosiran is set for February 4, 2020.
- Motley Fool
Alnylam Adds on Sales, Looks to Pipeline for Further Growth
The biotech could go from one to four marketed drugs in a little over a year.
- Thomson Reuters StreetEvents
Edited Transcript of ALNY earnings conference call or presentation 6-Aug-19 12:00pm GMT
Q2 2019 Alnylam Pharmaceuticals Inc Earnings Call
- Zacks
Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.
Motley FoolAlnylam Pharmaceuticals Inc (ALNY) Q2 2019 Earnings Call Transcript
ALNY earnings call for the period ending June 30, 2019.
- Zacks
Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid
Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
- Zacks
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of -1.10% and -5.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
− Achieved Second Quarter 2019 ONPATTRO® Global Net Product Revenues of $38.2 Million with More Than 500 Patients on Commercial Product Worldwide –
- Benzinga
The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on ...
- Business Wire
Alnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP), and granted Priority Review for the NDA. A Priority Review designation is granted to medicines that the FDA has determined have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease, and FDA’s goal is to take action within six months compared to 10 months under standard review.
- Zacks
bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
- Zacks
Amgen (AMGN) Catches Eye: Stock Jumps 5.7%
Amgen (AMGN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q2 Earnings Expected to Decline
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
A Look At The Fair Value Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alnylam...
- Zacks
Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.
- Zacks
Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.
- Zacks
Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats both earnings and sales estimates in the second quarter of 2019 and raises 2019 guidance.
- Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2019 on Tuesday, August 6, 2019, before the U.S. financial markets open. To access the call, please dial 800-263-0877 (domestic) or 646-828-8143 (international) five minutes prior to the start time and refer to conference ID 9566932. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to conference ID 9566932.
- CNW Group
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
MISSISSAUGA, ON , July 23, 2019 /CNW/ - Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the Health Canada approval and immediate availability of ONPATTRO® (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis3. ONPATTRO is the only treatment in Canada indicated for all stages of polyneuropathy associated with hATTR amyloidosis, a progressive, debilitating, chronic and often fatal disease.
